Press release
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update
Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs Announced a global license and collaboration agreement with
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs\n Announced a global license and collaboration agreement with Biogen to develop and commercialize pegylated CB 2782 for Dry AMD SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced its operating and financial results for the fourth quarter and full-year ending December 31, 2019 and provided a corporate update. “We made exceptional progress in both our subcutaneously-dosed (SQ) MarzAA (FVIIa) and SQ DalcA (FIX) programs this past year. Earlier this month at EAHAD, positive data was presented in an oral presentation from the Company’s Phase 2b SQ DalcA trial in subjects with hemophilia B clearly demonstrating efficacy and safety. We also presented data from MarzAA and Factor IX gene therapy programs in three posters,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “Catalyst’s therapies have demonstrated the potential to effectively treat hemophilia subcutaneously in a $3.4 billion market.” Dr. Usman continued, \"Additionally, our February 2020 financing combined with our current cash provides funding through several major milestones for our lead Phase 3 ready MarzAA and Phase 2b DalcA product candidates, as well as our FIX gene therapy and complement inhibitor programs.\" Recent Milestones: Announced a global license and collaboration agreement with Biogen Inc. to develop and commercialize pegylated CB 2782 and other anti-C3 proteases for the potential treatment of dry age-related macular degeneration (dAMD) and other disorders. Under terms of the agreement, Biogen is solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. Catalyst received a $15 million upfront payment for the transfer of an exclusive license and the related know-how; and is eligible to receive up to $340 million in clinical, regulatory and commercial milestone payments plus future tiered royalties based on net sales. Appointed Sharon Tetlow and Geoffrey Shiu Fei Ling, M.D., to its Board of Directors. Marzeptacog alfa (activated) – MarzAA, subcutaneously administered next-generation engineered coagulation Factor VIIa: Presented two posters at the annual ASH ...